Weight loss drugs: Scaling up

Weight loss drugs have pushed the obesity therapeutics market to an inflection point, reshaping not only patient behaviour, healthcare spending and investor expectations, but also potentially the global economic outlook, as lower obesity rates could promise higher productivity and reduced long term healthcare costs.

In this episode of the Barclays Brief, Patrick Coffey speaks with Emily Field, Head of US Biopharmaceuticals Equity Research, to break down the forces driving this shift.

They pinpoint the key accelerants: the arrival of oral versions, rapid uptake among consumers, shifting cash‑pay models, intensifying pricing pressure, and fierce competition facing the early leaders.

At the core, the episode answers this question: as these medicines move from specialist treatments to mass‑market consumer products, how will they reshape the market and determine who wins economically?

They also look ahead to the sector’s next phase, from ex‑US adoption and earnings signals to new entrants, combination therapies and future applications in areas such as addiction.

Clients can read more on Barclays Live:

• There’s no place like home; initiating coverage on U.S. Biopharmaceuticals

• Brave New World: Goodbye MFN, Hello Pipeline

• Protein Boom: Be prepared…

Survey source: KFF Health Tracking Poll

Important Content Disclosures

Important non-Research Content Disclosures

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(46)

Nuclear fusion: Tomorrow's solution to today's problem

Nuclear fusion has long been viewed as a transformational energy breakthrough, capable of delivering abundant, zero-carbon at operation energy by recreating the same reaction that powers the sun. Rece...

18 Aug 12min

Japan: Why the world is watching

Little more than a week ago, a rare, coordinated US-Japan intervention to support the yen caught investors’ attention. Coupled with rising expectations of another Bank of Japan (BoJ) rate hike and Pri...

11 Aug 10min

US equities: Beyond the pullback

After a spring sell-off and renewed summer weakness in technology stocks, uncertainty has remained a defining feature of the investment landscape. During the market sell-off following the start of the...

4 Aug 10min

AI credit supply tests market capacity

The AI buildout is fuelling a wave of new credit supply, and the sheer volume of debt is starting to test the market's capacity to absorb it. Year-to-date, the AI ecosystem has accounted for roughly 2...

28 Jul 9min

Challenging market consensus

Markets can become crowded around consensus views. In this episode of the Barclays Brief, Patrick Coffey is joined by Brian Kuritzky from our Rates Sales team to explore potential investor complacency...

21 Jul 9min

Cooling the AI buildout

Power constraints have dominated the conversation around AI infrastructure, but the buildout is facing a broader convergence of execution risks. Cooling, water use, permitting, labour shortages and gr...

14 Jul 8min

Opportunities in Asian Equities

Investor positioning across Asian equities is shifting, with opportunities increasingly driven by market-specific factors rather than a single regional or thematic narrative.In this episode of Barclay...

7 Jul 9min

Brexit, Burnham and Britain's Next Decade

Ten years after the Brexit referendum, many studies assess the effects on the UK economy as negative, pointing to weaker growth, lower investment and a tighter fiscal backdrop as its legacy. But the f...

30 Jun 10min